Is psychedelic-assisted therapy the next step in workplace wellness?

What if employers could improve mental health, lower costs, and boost retention by offering treatments once considered unconventional?Brett Gelbord sits down with Jillie Gordon Foerster of Dykema’s Employee Benefits Group and Sherry Rais, Co-Founder & CEO of Enthea, to explain how ketamine-assisted therapy, psilocybin therapy, and non-psychedelic options like the stellate ganglion block are becoming part of workplace wellness strategies. Listen as they examine how these treatments support employees who need help the most, why the data behind them is gaining attention, and what it takes to seamlessly integrate these services with their carrier.To hear more episodes, be sure to subscribe to Dykema’s YouTube channel, the Cannabis Law Blog, or by searching “A Higher Law” wherever you get your podcasts.Find more on Brett here.Find more on Jillie here.Find more on Sherry and Enthea here.To hear more episodes, visit DykemaPodcasts.com, our YouTube page, or search “A Higher Law” wherever you get your podcasts.Subscribe to Dykema’s Cannabis Law BlogLearn more about Dykema’s cannabis groupFollow Dykema on LinkedIn